9:49 AM
 | 
Jun 21, 2018
 |  BC Innovations  |  Translation in Brief

PHIP the script

How one new target could treat three tough cancers lacking common mutations

Cancers lacking key molecular signatures targeted by precision therapies are among the most challenging to treat, but a new study has identified a target, PHIP, for three of those difficult tumor types.

A group led by researchers at California Pacific Medical Center Research Institute (CPMCRI) and the University of California San Francisco first identified a role for pleckstrin homology domain interacting protein (PHIP) in cancer in a 2012 Proceedings of the National Academy of Sciences paper that showed PHIP as a marker and potential metastasis mediator in triple-negative melanomas, which...

Read the full 436 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >